New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

NEXT STORY
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
PREV STORY
Anaqua Lands Patent Management Deal with the U.S. Army Medical Research and Development Command
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

LifeMD Expands Patient Offerings by Acquiring Leading Allergy Telehealth Platform

author_avatar
NASDAQ Market News

Teladoc Health Reports Fourth-Quarter and Full-Year 2019 Results

author_avatar
NASDAQ Market News

Veterinary Therapeutics Market to Grow at 5.8% CAGR, Driven by Recent Developments in Veterinary Drugs, says Fortune Business Insights

author_avatar
NASDAQ Market News